Osmotherapy constitutes a first-line intervention for intracranial hypertension management. However, hyperosmolar solutes exert various systematic effects, among which their impact on systemic haemodynamics is poorly clarified. This review aims to appraise the clinical evidence of the effect of mannitol and hypertonic saline (HTS) on cardiac performance in neurosurgical and neurocritical care patients.
Introduction
Elevated intracranial pressure (h-ICP) has long been identified as a key factor for the development of secondary brain injury in patients with intracranial pathology. Among the various strategies used to reduce the intensity and duration of h-ICP, osmotherapy with either mannitol or hypertonic saline (HTS) is the recommended first-line medical intervention for optimising cerebral perfusion through brain relaxation and hence preventing pertinent neurological deterioration [1] . The fundamental concept of the effectiveness of hyperosmolar solutes involves an acute augmentation of blood osmolality, combined with bloodbrain barrier impermeability to mannitol and sodium, which facilitates water extraction from brain tissue to intravascular compartment [2] .
Although water shift achieves a substantial reduction of brain bulk, it can potentially modify cerebral and systemic haemodynamics in an important manner. Possible theories include an increase of systemic intravascular volume, which results in a decrease of serum viscosity with a concomitant augmentation of both cardiac output (CO) and blood pressure; the latter effect leads to a fall of cerebral blood flow due to compensatory cerebral vasoconstriction [3] . With mannitol, this is promptly followed by a profound diuresis, often leading to hypovolaemia. Considering that HTS has no diuretic properties, the volume expansion is sustained for a considerable time, thus giving it a distinct superiority in the setting of hypovolaemia (Table 1) [3] [4] [5] .
Mannitol, a nonmetabolized alcohol derivate of mannose, was introduced for clinical use in 1961 and it has been used as osmotic agent for the treatment of brain oedema and h-ICP and for ensuring brain relaxation in neurosurgical patients undergoing craniotomy [6, 7] . However, in patients sustaining an acute brain injury, the clinical benefit of mannitol infusion, its use in traumatic brain injury setting has not yet been proven according to evidence-based medicine criteria; the treatment of brain oedema is supported by level II evidence [8] .
Clinical use of HTS has been introduced for prehospital intravascular volume restoration in patients with severe haemorrhage and is increasingly used for the treatment of brain oedema and h-ICP [9, 10] . Recent guidelines suggest the use of HTS as a second-line therapy in cases where mannitol fails to reduce ICP [8] . Despite hyperosmolar solutions being routinely used in neurosurgical and neurocritical care (NCC) patients for brain relaxation and ICP management [8] [9] [10] [11] [12] [13] [14] , there is scanty information on the time course of their haemodynamic effects.
The purpose of this systematic review (SR) is to report clinical evidence of the effects of mannitol or HTS infusion on cardiac performance and systemic haemodynamics as a primary endpoint, with changes of plasma osmolarity, electrolytes concentration and urinary output as secondary outcomes in neurosurgical and NCC patients.
Methods

Search strategy and study selection
This SR was conducted in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Metaanalyses) statement recommendations [15] and was registered in the PROSPERO database under the number CRD42017062358. An electronic literature research of PubMed, EMBASE, Cochrane Central Register of Controlled Trials and International Web of Science databases from their inception to 2017 was performed to detect clinical studies pertinent to the administration of mannitol or HTS in neurosurgical or NCC population for h-ICP management.
For literature search purposes the subject headings "mannitol" and "hypertonic solutions" combined with free text words as "brain injury", "cerebral oedema", "neurosurgical procedures", "craniotomy", "neurocritical care", "haemodynamics" or "cardiac output", were applied. The search strategy is presented in Appendix 1. An ultimate check of the databases was carried out on 10 July 2017. Based on the search strategy applied, two investigators (G.T. and M.C.) independently screened and assessed titles and abstracts of all studies, and identified and discarded those that were obviously irrelevant or duplicates. If eligibility could not be ascertained from the title or the abstract, the full text of the study was retrieved and those deemed suitable were reviewed for eligibility according to the study characteristics and clinical relevance. References in the selected papers were scrutinized for additional articles in a further effort to ensure that relevant publications were not missed. Any disagreement over eligibility was resolved by consensus or by a third investigator (F.B.), as appropriate.
Inclusion and exclusion criteria
To be eligible for this SR, publications had to meet the following inclusion criteria: (i) peer-reviewed original research articles of any study design (randomized controlled trials, observational studies, and case series), involving prospective or retrospective data collection; (ii) adult population (age >18 years); (iii) provision of complete data with respect to CO change from baseline to the last measurement after termination of the infusion of either mannitol or HTS (single bolus dose or repeated infusion); (iv) availability of full-text publication in English language.
Data extraction and quality assessment
A dedicated data extraction form was developed for recording all relevant details. The extracted data were as follows: publication details (author, year of publication), study design, details of the study population (underlying brain pathology and number of patients), intervention (mannitol or HTS concentration and dosage), type and timing of haemodynamic monitoring and findings related to primary or secondary outcomes of interest. The primary outcome measure was the effect of mannitol or HTS on cardiovascular variables, such as: CO or cardiac index (CI), mean arterial pressure (MAP), heart rate (HR), central venous pressure (CVP), stroke volume (SV), stroke volume variation (SVV) and systemic vascular resistance (SVR). Secondary outcomes included their impact on ICP, brain relaxation, plasma osmolality, electrolyte imbalance and urinary output. Selected full papers were critically appraised and quality-assessed, using the Jadad scale [16] and the ROBINS-1 tool [17] for randomized controlled trials (RCTs) and observational cohort studies, respectively. Additional information on intention-to-treat and withdrawal or dropout rate for RCTs were also recorded. The bias risk in each study was judged by Cochrane Collaboration Risk of Bias Tool [18] , which incorporates the following domains: sequence generation, allocation concealment, blinding (including participants and personnel, data collectors, outcome assessors), acquisition of data, selective outcome reporting and other sources of bias. Each item was classified as low, unclear or high risk of bias.
Results
Study selection
A total of 6437 records were retrieved from database search, of which 1177 were screened and identified as possible appropriate publications after filtering. After review of titles and abstracts, 122 studies were selected as being potentially eligible for inclusion in this systematic review. Of these, 96 were eliminated as double publications, and 26 were reviewed for possible inclusion in this SR. The full-text evaluation identified 18 studies as not appropriate, no full-text publication and non-observational or RCT studies, and were finally excluded. The selected eight articles consisted of four RCTs [19] [20] [21] [22] and three prospective [23] [24] [25] and 1 retrospective [26] observational studies, that enrolled a total of 182 adult patients. All these studies met the criteria to be included in the final qualitative appraisal, Table 1 Physiological and clinical effects of mannitol vs. hypertonic saline 
Description of included trials
Five studies were conducted in elective craniotomy setting [20] [21] [22] [23] 26] , while the remaining three enrolled NCC patients treated either for subarachnoid haemorrhage [9] or traumatic brain injury [24, 25] . Three studies included the administration of either mannitol [23, 25] or HTS [24] as a sole osmotherapy; four trials (two observational and two RCTs) compared mannitol with HTS [combined or not to hydroxyethyl starch (HES)] [20] [21] [22] 24] , and in one RCT, the haemodynamic effects of mixed HTS-HES solution were tested against placebo [19] . Haemodynamic effects of mannitol were recorded as primary outcome end-point in two of the included studies [23, 24] . The concentration and dose of HTS and mannitol varied among the included trials in an important manner. In detail, the tested doses for mannitol 20% ranged between 0.6 and 1 g kg -1 and for HTS 3-7.5% from 1.5 to 5.3 ml kg -1 , with a reported duration of infusion ranging from 10 to 30 min. A considerable variability was recorded in the timing of osmotic agents administration. As for the subgroup of patients subjected to craniotomy surgery, this was defined as 15 min before dura opening [23, 25] , 30 min before skull opening [21] , during scalp incision [20] or shortly afterwards the drilling for the first burr hole of craniotomy was performed [22] .
Outcomes were assessed at different time points after termination of osmotic agent administration (ranging from 1 min to 6 h), while in one RCT systemic haemodynamic parameters were recorded at two different phases during the infusion of the tested drugs [20] . The cut-off ICP values defined as a criterion for osmotherapy application in NCC patients ranged from 15 mmHg [23] to 20 mmHg [26] , whereas ethical issues in a placebo-controlled RCT dictated the administration of an osmotic agent for ICP values <20 mmHg [19] . Moreover, a notable discrepancy in the follow-up period was recorded ranging from 45 min [21, 22, 26 ] to 6 h [20] . The most common tool for continuous non-invasive estimation of CO was based on pulse contour analysis, which was applied in four studies [19] [20] [21] [22] , whereas transthoracic electrical bioimpedance and transoesophageal echocardiography were used alternatively in two other studies [23, 25] . CO assessment was accomplished with an invasive approach in only two studies, using a pulmonary artery catheter for this purpose [24, 26] .
Quality assessment and risk of bias estimation of the included trials
Methodological quality assessment of the studies included in the SR is summarized in Tables 2 and 3 . Among the included RCTs, a notable difference in quality was identified as two were appraised as of high quality [19, 20] and two of low quality. Blinding was performed only in two RCTs [19, 20] among which only one [20] incorporated blinding of all involved personnel and these also reported adequate allocation concealment and a sample size consideration or power calculations.
The risk of bias estimation of the eight studies included in this SR is summarized in Table 4 . Most of the studies enrolled are characterized by moderate to high risk of bias, due to under-reporting of data regarding randomization method or blinding. Publication bias analysis was not pursued, as data reporting CO changes were insufficient to conduct a valid meta-analysis.
Primary outcome measures
Data on CO, MAP and HR changes due to mannitol or HTS infusion being extracted from these studies, are pooled and presented in a timeline sequence, starting from the effects during infusion and up to 360 min follow-up.
Effects on CO. Two studies assessing mannitol as a sole osmotic agent, reported a CO increase lasting up to 15 min [23, 25] , while four studies that tested mannitol versus HTS, failed to identify any profound alteration in CO values, after mannitol infusion [20] [21] [22] 26] . Nonetheless, a notable augmentation of CO or CI in HTS-treated patients was a common finding in five out of the six studies involving the use of HTS [19, 20, 22, 24, 26] . The increase in CO was recorded either for a some time frame [22, 24, 25] or at all time points of assessment up to 2 h after infusion [19, 26] . The increase in CO became apparent upon 6 h post-infusion in only one RCT, with no particular differences in CO at earlier time points [20] . Due to significant heterogeneity and differences in reporting CO changes attributed to the infusion of osmotic agents, this outcome could not be metaanalysed.
Effects on MAP and HR. All eight selected studies evaluated the effects of mannitol or HTS on MAP. Mannitol induced a consistent MAP deterioration, which became apparent immediately after the end of the infusion and lasted up to 45 min thereafter [21, 22, 25] . A trend towards to MAP reduction, was also reported in HTStreated patients, but this effect was not of statistical importance [22] . The effect of osmotherapy on HR was Table 2 Critical appraisal of randomized controlled trials assessing osmotic agents in neurosurgical and neurocritical care patients using Jadad score Table 3 Critical appraisal of observational trials assessing osmotic agents in neurosurgical and neurocritical care patients using ROBINS-1 tool reported in six studies [19, [21] [22] [23] [24] [25] , ranging from a nonsignificant change [19, 22, 23 ] to a notable either increase or decrease compared to preinfusion values [21, 24, 25] . In detail, mannitol-induced an HR reduction lasting from 25 to 45 min after the end of infusion [25] , while an insignificant effect on HR was the common finding in three studies [21] [22] [23] . By contrast, the infusion of HTS was associated with an HR augmentation lasting up to 30 min postinfusion and subsequent normalization thereafter [24] , an HR reduction lasting up to 60 min postinfusion [21] , or no effect on HR. [19, 22] Effects on CVP, SV, SVV and SVR. In line with previous findings, a relative heterogeneity was also encountered in terms of CVP changes. These varied from nonsignificant [20, 26] to notable augmentation up to 15 min and 25 min after termination of HTS or mannitol administration, respectively [22] [23] [24] . Five of the selected studies incorporated SV or SVV as reliable indices of systemic haemodynamic status appraisal [20] [21] [22] [23] 25] . SV was positively affected by mannitol use for approximately 15 min [23, 25] , whilst in one RCT, the use of mannitol or HTS reduced or enhanced SV, respectively [22] . Three RCTs [20] [21] [22] applying pulse contour analysis for SVV estimation, showed either a constant decrease [20, 21] , or an increase after an initial fall [22] in HTS group, while the single report about the effect of mannitol on SVV revealed that after a brief initial fall, SVV remained in higher levels compared to baseline throughout the study period [22] . Despite the limited available evidence on the impact of mannitol or HTS on SVR, it occurred that both drugs induced a significant decline of this parameter, which seemed to be valid for a longer time in HTS-treated patients [23, 24] . Of note, comparative studies between the two osmotic agents failed to demonstrate any clinically significant difference in CO or CI and the other tested haemodynamic variables during the study course [20] [21] [22] 26] .
Secondary outcome measures
Effects on ICP and cerebral perfusion pressure. Data regarding the impact of osmotic agents on ICP or brain relaxation was provided in six studies, enrolling 176 patients [19-22, 24, 26] . In these studies, mannitol or HTS (as a sole agent or combined with HES 6%) consistently induced an ICP reduction with an associated cerebral perfusion pressure increase. Half of these studies identified a relative superiority of HTS over mannitol, in terms of cerebral haemodynamics, with a peak effect being recorded at 60 min after the end of HTS infusion [19, 24, 26] . Two RCTs, reported equivalent brain relaxation scores between both osmotic agents [20, 22] , as this was assessed by neurosurgeons using the four-point brain relaxation scale [27] , while another RCT, using a three-point dural tension score for brain relaxation assessment [28] , identified a considerable superiority of HTS over to mannitol for brain relaxation attainment [21] .
Data from two RCTs [19, 22] and two observational studies [22, 26] , involving ICP monitoring, demonstrated that improvement of cardiac performance as a result of osmotic agent administration, was associated with a concomitant optimization of cerebral haemodynamics, an effect more apparent in HTS-treated patients [19, 22, 24, 26] .
Effects on osmolality and electrolytes. Three trials provided complete data with respect to osmolality, which was consistently maintained above baseline value up to 360 min after the infusion of either osmotic agent [20, 21, 24] . Nevertheless, the increase in serum osmolality was more prominent after HTS than mannitol infusion [21] . Five trials provided details regarding the changes of various electrolytes [20-22, 24, 26] . Serum sodium levels were consistently elevated after HTS administration throughout the study period [20-22, 24, 26] . The magnitude of hypernatraemia was not associated with the osmotic load of HTS solution or the dose administered, whilst serum sodium levels ranged within acceptable limits. On the contrary, Cardiac output changes after osmotherapy mannitol promoted sodium level reduction, reaching levels below the lower limit of normalcy in one trial [20, 22] . Chloride and potassium changes were recorded in two studies [22, 24] . HTS promoted an increase of chloride with a concomitant transient reduction of potassium; the reverse observed in mannitol group [22, 24] .
Evidence on urine output. Data on urine output were recorded in six studies, which consistently showed that mannitol infusion promoted an augmentation of urine output lasting up to 6 h [20] [21] [22] [23] [24] [25] . Two RCTs demonstrated that mannitol had a more potent effect on urine output increase than HTS [21, 22] . Higher fluid volume infusion emerged as a necessary treatment of mannitol-induced hypovolaemia [20] [21] [22] . The basic characteristics of the reviewed studies and osmotherapy-related outcomes are shown in Table 5 .
Discussion
This SR reports available clinical literature on cardiovascular effects of mannitol or HTS use in neurosurgical and NCC patients. Despite the limited number of studies being suitable for this SR, it is possible to extract some findings: (i) Both mannitol and HTS induced an increase in CO and other recorded systemic haemodynamic variables (CVP, SV, SVV). CO increase was more pronounced after HTS than mannitol administration.
(ii) Mannitol and HTS infusion was associated with a trend towards to MAP and HR reduction. (iii) Both osmotic agents induced an ICP reduction and brain relaxation, an effect that seems to be more prominent in HTStreated patients. (iv) HTS infusion promoted notably higher plasma sodium levels compared to mannitol, without any differences in serum osmolality, which was increased by both osmotic agents. (v) Mannitol induced a more potent diuretic than HTS. CO plays a fundamental role in brain perfusion; however, the relationship between changes in CO and cerebral circulation remains largely speculative and it should be integrated into the framework of cerebral autoregulation [29] . Overall, cerebral perfusion relates to CO and blood pressure and to their distinct effects on cerebral haemodynamics [29] . Therefore, enhancement of cardiac performance and optimization of fluid balance, could improve brain perfusion especially in patients with impaired cardiac function [30, 31] . Infusion of osmotic therapies -mannitol and HTS -promote a water shift from intracellular to the extracellular (and thus intravascular) compartments and direct peripheral vasodilation, ultimately leading to CO augmentation [3, 32, 33] . Moreover, HTS can directly improve myocardial performance through a reduction in myocyte oedema and an increase in myocardial uptake of calcium with restores transmembrane potential [33, 34] . Current evidence confirms CO enhancement after infusion of either mannitol or HTS [32] [33] [34] . The different methods used to evaluate systemic haemodynamic changes (pulse contour analysis, pulmonary artery catheter, transoesophageal echocardiography or transthoracic electrical bioimpedance) might be -in part -responsible for the recorded differences. Despite the various monitoring approaches, comparative studies did not report any differences between the two osmotic agents, in terms of their effects on CO or CI [20] [21] [22] 26 ].
An early but transient decline in MAP after HTS was recorded by a single study, whilst this was a more consistent finding in mannitol-treated patients in whom hypotension persisted up to 45 min post-infusion [21, 22, 25] . Nonetheless, validity of these findings is questionable as half of the studies reporting changes of blood pressure, failed to show any effect [19, 23, 24, 26] . Possibly, differences in fluid therapy are partially responsible for the short-term drop in blood pressure after mannitol infusion [20] [21] [22] .
Intravascular volume expansion induced by the sustained increase in plasma osmolality -being witnessed in both osmotic compounds at all time points of assessment -is also reflected by the augmentation of CVP reported in three out of five studies assessing this parameter [20, [22] [23] [24] 26] , an effect being evident up to 15 min after HTS infusion and 25 min after mannitol infusion [22] [23] [24] . Since equivolume, equiosmolar solutions were applied, it is conceivable that no noticeable difference in CVP values between mannitol and HTS groups could be demonstrated [20, 22, 26] .
A consistent haemodynamic effect was the decline of peripheral vascular resistance accompanied by an enhancement of CO values [23, 24] . Hypertonic solutions improve systemic haemodynamics through mechanisms other than changes in serum osmolality, involving myocardial contractility enhancement and capillary systemic vasculature dilatation [33, 35] .
Osmotic therapy is routinely used to control h-ICP in a wide range of acute conditions and thus most of the clinical knowledge on the application of mannitol and HTS has focused on their brain relaxation and ICP-lowering properties [1, 3] . Prior meta-analyses have suggested that HTS could be equivalent or even more effective than mannitol at reducing ICP [10, 14, [36] [37] [38] . However, our SR showed that both osmotic agents are equally effective in brain relaxation or cerebral haemodynamics optimization [19-22, 24, 26, 38] , no clear superiority of either osmotic agent could be demonstrated due to the limited quantity and quality of the available data [20] [21] [22] 26] . A more detailed analysis of data from this SR revealed that the fall in ICP and rise in cerebral perfusion pressure are closely related to the improvement on cardiac performance in both groups [19, 22, 24, 26] .
Electrolyte abnormalities are the adverse effects most commonly encountered in hyperosmolar therapy with a clinical importance equivalent to its brain relaxation properties [9, 32] . In line with previous reports [9, 35, 39, 40] , our SR confirmed that the administration of HTS heightened the levels of serum sodium, which was sustained for 6 h, and promoted a temporary reduction of potassium [20-22, 24, 26] . In contrast, mannitol caused a transient acute dilutional hyponatremia [20, 22, 26] , with a concomitant stepwise increase of potassium over time [22] . However, sodium levels tend to normalize over time, as a result of the diuretic effects of mannitol [28, 34, 35, 41] .
While all hyperosmolar agents promote diuresis, HTS exerts a weaker diuretic effect than mannitol, possibly because it stimulates the release of antidiuretic hormones [9, 39, 40] . By contrast, mannitol infusion could induce hypovolaemia through an increase in diuresis [13, [20] [21] [22] [23] [24] [25] 28 ].
Table 5
Characteristics of the included studies Considering that mannitol is used as first-choice hyperosmolar solution -for its effectiveness of controlling h-ICP -the potential risk of secondary hypovolaemia due to its diuretic effect, which in turn requires larger fluid replacement to maintain haemodynamic homeostasis, is an issue of concern [9] . Considering that hypovolaemia could be detrimental after brain injury, this has led to a resurgence of interest in the use of HTS in NCC setting, as it seems that the advantage of HTS in this setting is the maintenance of blood pressure with low volume resuscitation and thus avoiding potentially iatrogenic ICP increase [8] . This aspect is further supported by a recent SR of HTS compared to isotonic solution for perioperative fluid management, which indicates that HTS can reduce the intravenous fluid replacement needs in patients undergoing surgery [41] .
Limitations
Several key limitations of this review need to be considered. Only eight studies with a limited number of participants reported the haemodynamic effects of mannitol or HTS and changes of systemic haemodynamics served as primary end-point in only five of them. It is therefore not surprising that important contextual parameters, such as brain pathologies, methodological approaches, target haemodynamic variables, timeline for haemodynamic variables recording, and approaches for CO evaluation, presented considerable heterogeneity among the included studies. In some of these studies, isolated numerical reporting of CO, MAP and ICP without the appropriate clinical context, baseline haemodynamic status assessment and evaluation of confounding factors, such as the use of vasoactive medications for cerebral haemodynamics optimization, makes interpretation of the findings even more challenging.
Finally, while this study aimed to assess the impact of either osmotic agent on ICP and brain relaxation via alterations of cardiac performance, it should be emphasized that optimization of these pathophysiological end-points cannot guarantee a satisfactory neurological outcome.
Implication for research
From these review findings, arises an essential and a clear area in need of high-quality research to address the possible superiority of HTS compared to mannitol, as to cardiac performance enhancement and subsequent improvement of cerebral haemodynamics. Clear reporting of dosing and osmotic load strategy, cointerventions administered, and a priori defined haemodynamic goal are strongly recommended. Furthermore, it remains to be delineated the underlying pathophysiology for CO improvement after HTS administration and the safety of this volume-expanding effect in patients with brain pathology and concurrent myocardial dysfunction. Given the challenging haemodynamic sensitivities and distinctive needs for optimization of cerebral autoregulation in neurosurgical and NCC patients, the validation of an effective and safe osmotic therapy would prove invaluable in the future care of this unique population. 
Conclusions
In this systematic review, we report clinical evidence on the relationship between systemic and cerebral haemodynamic effects after the application of osmotic therapies -mannitol or HTS -in neurosurgical and NCC setting. Although available data suggest that both mannitol and HTS promote an augmentation of CO, this effect seems to be more pronounced after HTS than mannitol administration. Furthermore, mannitol induces an enhancement of diuresis, while HTS engenders an increase of plasma sodium concentration. These effects might be, in part, responsible for the overall therapeutic effects associated with osmotic therapies. Further research is warranted to define optimal time and dosing and the impact on outcome.
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Appendix 1
Complete research strategy
Searching strategy, combining free text and medical subject headings (MeSH terms) was set up for PUBMED as follows: Searching strategy, using combination of terms was set up for EMBASE as follows:
SUBJECT HEADING: (("mannitol" OR "hypertonic saline"), USED FOR (cardiac output OR hemodynamics OR craniotomy OR neurosurgical procedures OR cerebral oedema OR brain injury OR neurocritical care)).
Searching strategy, using combination of terms was set up for The International Web of Science as follows:
TOPIC: (("mannitol" OR "hypertonic saline") AND (cardiac output OR hemodynamics OR craniotomy OR neurosurgical procedures OR cerebral oedema OR brain injury OR neurocritical care)).
Searching strategy, using combination of terms was set up for The Cochrane Central Register of Controlled Trials (CENTRAL) as follows:
#1. "mannitol": ti,ab,kw and "cardiac output" in Trials. #2. "mannitol": ti,ab,kw and "hemodynamics" in Trials. #3. "mannitol": ti,ab,kw and "craniotomy" in Trials. #4. "mannitol": ti,ab,kw and "neurosurgical procedures" in Trials. #5. "mannitol": ti,ab,kw and "cerebral oedema" in Trials. #6. "mannitol": ti,ab,kw and "brain injury" in Trials. #7. "mannitol": ti,ab,kw and "neurocritical care" in Trials. #8. "hypertonic saline": ti,ab,kw and "cardiac output" in Trials. #9. "hypertonic saline": ti,ab,kw and "hemodynamics" in Trials. #10. "hypertonic saline": ti,ab,kw and "craniotomy" in Trials. #11. "hypertonic saline": ti,ab,kw and "neurosurgical procedures" in Trials. #12. "hypertonic saline": ti,ab,kw and "cerebral oedema" in Trials. #13. "hypertonic saline": ti,ab,kw and "brain injury" in Trials. #14. "hypertonic saline": ti,ab,kw and "neurocritical care" in Trials.
